Tag Archives: Global

Fixing Innovation: Lilly's CEO Says Why, and How

By Ben Comer | Published: June 11, 2012
Following his keynote address last week at the Financial Times US Healthcare and Life Sciences Conference in New York, Eli Lilly CEO John Lechleiter huddled into a corridor to speak with PharmExec about his agenda as incoming chairman of PhRMA, and how to fix innovation.
Posted in Europe, Events, FDA, Global, IP, Legal, Market Access, Meetings, People, R&D, Regulatory, Safety, Strategy, Technology, healthcare, leadership, pricing | Also tagged , , , , , , , , , , , , | 1 Comment

Indian Government Proposes Ban on Physician Gifts

By Ben Comer | Published: June 6, 2011
India’s Department of Pharmaceuticals released a 14-page “voluntary code” for drug marketers, which includes a strict ban on gifts to prescribers, among other things. The code, which is open for public comment until June 30th, states that “no gifts, pecuniary advantages or benefits in kind may be supplied, offered or promised to persons qualified to prescribe” [...]
Posted in Advertising, Emerging Markets, Global, Marketing, Medical Education, Strategy | Also tagged , , , , , | Leave a comment

California Life Sciences to Partner with China

By Ben Comer | Published: April 13, 2011
BIOCOM, a trade group representing Southern California’s life sciences industry, is ramping up partnership efforts in China to meet an emerging desire for novel drug therapies. While intellectual property (IP) protections and the Chinese government’s willingness to pay for expensive new products represent two large and lingering question marks, Joe Panetta, president and CEO at BIOCOM, [...]
Posted in Biotech, Emerging Markets, Global, IP, Market Access, R&D, leadership | Also tagged , , , | Leave a comment

Fixing Biotech's Broken Business Model

By Julian Upton | Published: December 22, 2010
Despite some notable successes, the global biotech industry has fallen short of expectations. Strategic collaborations have been on the increase, but there is now a need for more co-operation using new collaboration models, writes Jo Pisani. The current business model on which biotech has relied is flawed. Due to poor rates of return, investment has dried [...]
Posted in Biotech, Deals, Emerging Markets, Europe, Global, Guest Blog, R&D | Also tagged , , , , , , , | Leave a comment

Ireland's Economic Bailout to Sting Pharma

By Julian Upton | Published: December 1, 2010
Ireland’s favorable level of corporation tax remains untouched by the country’s economic rescue package, but drugmakers will still feel the pinch of the healthcare cuts. Despite pressure from France and Germany, Ireland has managed to secure its Euro 85 billion ($111 billion) rescue package from Europe and the International Monetary Fund without raising corporation tax, one [...]
Posted in Europe, Global, Regulatory | Also tagged , , , , | Leave a comment